Five Steps to Improve Cardiac Safety of Attention Deficit Hyperactivity Disorder Treatment.
作者信息
Dopheide Julie A, Stutzman Danielle L
机构信息
University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences Titus Family Department of Clinical Pharmacy (JAD) and Keck School of Medicine Department of Psychiatry and the Behavioral Sciences (JAD), LA General Medical Center, Los Angeles, CA (JAD).
Pediatric Mental Health Institute (DLS), Children's Hospital Colorado, Aurora, CO.
出版信息
J Pediatr Pharmacol Ther. 2024 Dec;29(6):670-673. doi: 10.5863/1551-6776-29.6.670. Epub 2024 Dec 9.
Abstract
摘要
相似文献
1
Five Steps to Improve Cardiac Safety of Attention Deficit Hyperactivity Disorder Treatment.改善注意力缺陷多动障碍治疗心脏安全性的五个步骤
J Pediatr Pharmacol Ther. 2024 Dec;29(6):670-673. doi: 10.5863/1551-6776-29.6.670. Epub 2024 Dec 9.
2
Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.与缓释混合安非他明盐相比，使用盐酸哌甲酯控释片进行兴奋剂治疗对改善患有注意力缺陷多动障碍的青少年驾驶员驾驶性能的相对益处。
Pediatrics. 2006 Sep;118(3):e704-10. doi: 10.1542/peds.2005-2947.
3
Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.儿童、青少年和成人注意力缺陷多动障碍药物的心血管安全性比较：系统评价和网状Meta分析。
Lancet Psychiatry. 2025 May;12(5):355-365. doi: 10.1016/S2215-0366(25)00062-8. Epub 2025 Apr 6.
4
Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients.用于治疗成年患者注意力缺陷/多动障碍的盐酸维拉佐酮缓释胶囊。
Expert Rev Neurother. 2023 Jul-Dec;23(11):945-953. doi: 10.1080/14737175.2023.2265068. Epub 2023 Oct 27.
5
Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.注意缺陷多动障碍儿童及青少年从哌甲酯或苯丙胺转换为托莫西汀的初步耐受性和疗效研究
Clin Ther. 2007 Jun;29(6):1168-77. doi: 10.1016/j.clinthera.2007.06.017.
6
Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.用于治疗注意力缺陷/多动障碍的托莫西汀与兴奋剂对比
Ann Pharmacother. 2006 Jun;40(6):1134-42. doi: 10.1345/aph.1G582. Epub 2006 May 30.
7
Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.患有共病抽动障碍的儿童注意力缺陷多动障碍（ADHD）的药物治疗。
Cochrane Database Syst Rev. 2018 Jun 26;6(6):CD007990. doi: 10.1002/14651858.CD007990.pub3.
8
Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.治疗注意缺陷多动障碍儿童患者的药物不良反应与情绪相关：美国食品和药物管理局不良事件报告系统数据库的比较分析。
J Clin Psychopharmacol. 2019 Jul/Aug;39(4):386-392. doi: 10.1097/JCP.0000000000001058.
9
Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release.评估 centanafadine 治疗成人注意缺陷多动障碍：与 lisdexamfetamine dimesylate、盐酸托莫西汀和维洛沙嗪缓释剂的匹配调整间接比较。
J Manag Care Spec Pharm. 2024 Jun;30(6):528-540. doi: 10.18553/jmcp.2024.30.6.528.
10
Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.与使用兴奋剂药物和托莫西汀治疗儿童注意力缺陷/多动障碍相关的阴茎异常勃起。
Ann Pharmacother. 2014 Oct;48(10):1350-5. doi: 10.1177/1060028014541791. Epub 2014 Jun 30.
本文引用的文献
1
Practice Pearls for Stimulant Treatment of Attention-Deficit/Hyperactivity Disorder in Youth.青少年注意缺陷/多动障碍兴奋剂治疗的实用要点
J Pediatr Pharmacol Ther. 2024 Jun;29(3):215-231. doi: 10.5863/1551-6776-29.3.215. Epub 2024 Jun 10.
2
Attention-Deficit/Hyperactivity Disorder Medications and Work Disability and Mental Health Outcomes.注意缺陷多动障碍药物与工作残疾及心理健康结局。
JAMA Netw Open. 2024 Mar 4;7(3):e242859. doi: 10.1001/jamanetworkopen.2024.2859.
3
ADHD Pharmacotherapy and Mortality in Individuals With ADHD.注意缺陷多动障碍的药物治疗与患有注意缺陷多动障碍个体的死亡率
JAMA. 2024 Mar 12;331(10):850-860. doi: 10.1001/jama.2024.0851.
4
Association of Cannabis Use With Cardiovascular Outcomes Among US Adults.美国成年人中使用大麻与心血管结局的关联。
J Am Heart Assoc. 2024 Mar 5;13(5):e030178. doi: 10.1161/JAHA.123.030178. Epub 2024 Feb 28.
5
Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases.注意缺陷多动障碍药物与长期心血管疾病风险。
JAMA Psychiatry. 2024 Feb 1;81(2):178-187. doi: 10.1001/jamapsychiatry.2023.4294.
6
Long-Term Cardiovascular Effects of Medications for Attention-Deficit/Hyperactivity Disorder-Balancing Benefits and Risks of Treatment.注意缺陷多动障碍药物治疗的长期心血管影响——权衡治疗的益处与风险
JAMA Psychiatry. 2024 Feb 1;81(2):123-124. doi: 10.1001/jamapsychiatry.2023.4126.
7
Adverse Impact of Cannabis on Human Health.大麻对人类健康的不良影响。
Annu Rev Med. 2024 Jan 29;75:353-367. doi: 10.1146/annurev-med-052422-020627. Epub 2023 Aug 15.
8
Trends in Stimulant Prescription Fills Among Commercially Insured Children and Adults - United States, 2016-2021.2016-2021 年美国商业保险覆盖的儿童和成人兴奋剂处方数量趋势。
MMWR Morb Mortal Wkly Rep. 2023 Mar 31;72(13):327-332. doi: 10.15585/mmwr.mm7213a1.
9
Assessment and management of cardiovascular complications in eating disorders.饮食失调中心血管并发症的评估与管理。
J Eat Disord. 2023 Jan 30;11(1):13. doi: 10.1186/s40337-022-00724-5.
10
Long-term methylphenidate exposure and 24-hours blood pressure and left ventricular mass in adolescents and young adults with attention deficit hyperactivity disorder.患有注意力缺陷多动障碍的青少年和青年长期使用哌甲酯对24小时血压及左心室质量的影响
Eur Neuropsychopharmacol. 2022 Nov;64:63-71. doi: 10.1016/j.euroneuro.2022.09.001. Epub 2022 Oct 7.
Zotero 插件